Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Acquired by a private equity firm in 2021
|
| gptkbp:business_model |
partnerships and collaborations
|
| gptkbp:can_lead_to |
IMG N151
IMG N632 |
| gptkbp:ceo |
gptkb:Mark_Enyedy
|
| gptkbp:clinical_trial |
gptkb:healthcare_organization
ovarian cancer ongoing Phase 1 Phase 2 Phase 3 diverse patient populations published in peer-reviewed journals multiple sites globally various phases of development |
| gptkbp:collaborations |
gptkb:Johns_Hopkins_University
gptkb:University_of_California,_San_Francisco with academic institutions with pharmaceutical companies with research institutions |
| gptkbp:committee |
composed of industry experts
|
| gptkbp:community_engagement |
involvement in cancer awareness initiatives
|
| gptkbp:employees |
approximately 200
|
| gptkbp:focus |
cancer therapeutics
|
| gptkbp:focus_area |
immuno-oncology
|
| gptkbp:founded |
gptkb:1981
|
| gptkbp:future_plans |
expansion of drug pipeline
|
| gptkbp:headquarters |
gptkb:Waltham,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Immuno Gen
|
| gptkbp:invention |
multiple patents in drug development
|
| gptkbp:investment |
Venture capital firms
engagement with shareholders |
| gptkbp:language_of_instruction |
multiple drug candidates
|
| gptkbp:market_cap |
approximately $1 billion (2021)
|
| gptkbp:partnership |
gptkb:temple
gptkb:Bristol-Myers_Squibb |
| gptkbp:partnerships |
with biotech firms
|
| gptkbp:products |
gptkb:Mirvetuximab_soravtansine
gptkb:Trastuzumab_emtansine |
| gptkbp:publishes |
numerous publications in journals
|
| gptkbp:receives_funding_from |
from government grants
from private investors |
| gptkbp:regulatory_compliance |
FDA approval for certain drugs
|
| gptkbp:research_and_development |
significant investment
|
| gptkbp:research_areas |
oncology
targeted delivery of drugs |
| gptkbp:research_focus |
targeted cancer therapies
|
| gptkbp:revenue |
$50 million (2020)
|
| gptkbp:symbol |
IMGN
|
| gptkbp:technology |
Antibody-drug conjugates
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.immunogen.com
|
| gptkbp:bfsParent |
gptkb:Ariad_Pharmaceuticals
|
| gptkbp:bfsLayer |
4
|